Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

Abstract Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML), but patients still experience treatment‐limiting toxicities or therapeutic failure. To investigate the real‐world use and outcomes of imatinib in patients with CML in Australia, a retrospec...

Full description

Bibliographic Details
Main Authors: Josephine A. Adattini, Annette S. Gross, Nicole Wong Doo, Andrew J. McLachlan
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Pharmacology Research & Perspectives
Subjects:
anticancer drugs
chronic myeloid leukemia
imatinib
pharmacoepidemiology
precision medicine
real‐world evidence
Online Access:https://doi.org/10.1002/prp2.1005

Internet

https://doi.org/10.1002/prp2.1005

Similar Items